Insmed, Inc.
INSM
$100.60
+0.12%
Insmed, Inc. is a commercial-stage biopharmaceutical company whose portfolio spans three therapeutic areas — Respiratory, Immunology & Inflammation, and Neuro & Other Rare diseases — anchored by two marketed respiratory products, Arikayce (amikacin liposome inhalation suspension) and Brinsupri (brensocatib), alongside clinical-stage assets including TPIP, INS1148, and INS1201 and a preclinical platform spanning gene therapy, AI-driven protein engineering, and RNA end-joining. The company has evolved from a single-product rare-disease player into a multi-asset commercial platform, with brensocatib positioned as a potential first-in-class DPP1 inhibitor for bronchiectasis and other neutrophil-driven diseases, a franchise that could meaningfully broaden its revenue base beyond Arikayce. The current investor narrative is dominated by the brensocatib launch trajectory and pipeline optionality, with the FDA's September 2026 acceptance of a priority-review filing to expand Arikayce's label serving as a fresh near-term catalyst. At the same time, the stock has been a notable underperformer over the past year, with shares down sharply from their 52-week high as investors weigh heavy R&D and launch-related spending against the timing and magnitude of the eventual revenue ramp — a classic commercial-stage biotech tension between cash burn today and franchise value tomorrow.…
INSM
Insmed, Inc.
$100.60
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold with a speculative growth tilt. The core thesis is that Insmed offers a genuine commercial-stage biotech inflection — Q2 2026 revenue of $425.5M (+296% YoY) and EPS of -$0.06 — but the current valuation (forward P/E 143.4x, P/S 61.3x) already discounts much of the brensocatib and Arikayce opportunity. The analyst consensus is strong buy with an average target of $197.74 (78% upside), but the stock's 37.3% YTD decline and -$837.7M TTM free cash flow argue for patience until the revenue ramp is confirmed.
Supporting evidence for a constructive stance includes: (1) gross margin of 79.4% TTM and 84.2% in Q2 2026, which provides high incremental profitability as revenue scales; (2) Q2 operating income of -$1.5M versus -$312.9M a year ago, showing rapid operating leverage; (3) 23 analysts with a strong buy consensus and a low target of $169, still 52% above the current price; and (4) a current ratio of 3.83 and beta of 0.817, offering balance-sheet resilience and lower volatility than the broader market. However, the forward P/E of 143.4x and negative EV/EBITDA of -32.0x mean the stock is priced for perfection relative to peers and its own history.
The biggest risks that could invalidate the thesis are: (1) a brensocatib launch that undershoots the $6.37B average revenue estimate for the coming year; (2) a delay or rejection of the Arikayce label expansion, removing a key near-term catalyst; and (3) continued cash burn forcing a dilutive equity raise below analyst targets. The rating would upgrade to Buy if revenue growth sustains above 100% YoY for two more quarters and free cash flow burn narrows below $500M annualized, or downgrade to Sell if Q3 revenue falls below $400M or the Arikayce filing receives a complete response letter. On valuation, INSM is overvalued on current earnings but potentially fairly valued on 2027-2028 estimates if the launch trajectory holds — a high-risk, high-reward profile.
Sign up to view all
INSM 12-Month Price Forecast
Insmed presents a classic commercial-stage biotech inflection story: revenue is accelerating rapidly (Q2 2026 +296% YoY), gross margins are near 80%, and the brensocatib/Arikayce franchise could drive multi-year growth. However, the valuation is extreme on every near-term metric (forward P/E 143.4x, P/S 61.3x), free cash flow is deeply negative at -$837.7M TTM, and the stock has been in a persistent downtrend (-37.3% YTD). The analyst consensus is overwhelmingly bullish, but the market is clearly demanding proof of the revenue ramp before re-rating the shares. I would upgrade to bullish if Q3 2026 revenue exceeds $500M and free cash flow burn narrows below $150M for the quarter, or downgrade to bearish if revenue misses $400M or the Arikayce label expansion is delayed.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $197.74 and implied upside of +96.6% versus the current price.
Average Target
$197.74
0 analysts
Implied Upside
+96.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$169 - $243
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: INSM Investment Factors
The bear case currently has stronger near-term evidence: INSM is down 37.3% YTD, burning $837.7M in TTM free cash flow, and trades at a forward P/E of 143x with negative trailing earnings. However, the bull case rests on a genuine fundamental inflection — Q2 2026 revenue of $425.5M grew 296% YoY, EPS improved to -$0.06, and 23 analysts maintain a strong buy with a $197.74 average target. The single most important tension is whether the brensocatib/Arikayce revenue ramp can scale fast enough to justify the extreme valuation before cash reserves or investor patience run out; if Q3/Q4 revenue growth decelerates or the Arikayce label expansion disappoints, the stock could retest its 52-week low of $90.39, while successful execution could drive a sharp re-rating toward analyst targets.
Bullish
- Analyst consensus strong buy, huge upside: All 23 covering analysts rate INSM a strong buy (recommendation mean 1.21), with an average target price of $197.74 — implying roughly 78% upside from the current $111.12. Even the lowest analyst target of $169 sits about 52% above the current price, suggesting the sell-off has decoupled from fundamental expectations.
- Revenue inflecting sharply, Q2 EPS near breakeven: Q2 2026 revenue reached $425.5M, up 296% year-over-year, and diluted EPS improved to -$0.06 from -$1.70 in the year-ago quarter. The sequential revenue ramp from $306.0M in Q1 to $425.5M in Q2 shows commercial execution is accelerating as brensocatib (Brinsupri) contributes.
- Gross margins near 80%, operating leverage emerging: Gross margin stands at 79.4% (TTM) and 84.2% in Q2 2026, providing a high-margin base as revenue scales. Q2 operating income was only -$1.5M versus -$312.9M a year earlier, demonstrating rapid operating leverage as R&D and SG&A growth moderates relative to revenue.
- Arikayce label expansion catalyst with priority review: The FDA accepted Insmed's filing to expand Arikayce's label with priority review in September 2026, a near-term catalyst that could significantly widen the drug's addressable market. This comes on top of brensocatib's first-in-class DPP1 positioning in bronchiectasis, adding a second growth vector.
Bearish
- Extreme valuation on every earnings metric: INSM trades at a trailing P/S of 61.3x, forward P/E of 143.4x, and price-to-book of 50.3x, with negative trailing earnings (P/E -27.2x) and negative EV/EBITDA (-32.0x). Even on forward estimates, the market is pricing in flawless execution of a multi-year revenue ramp that has yet to be proven.
- Massive cash burn and negative free cash flow: TTM free cash flow is -$837.7M, with Q2 2026 R&D alone at $210.0M and SG&A at $247.5M. Net margin is -2.1% and operating margin -1.94%, meaning the company remains unprofitable and dependent on external financing or continued revenue acceleration to reach breakeven.
- Severe underperformance and broken momentum: The stock is down 27.3% over one year, 31.6% over six months, and 37.3% year-to-date, with a max drawdown of -56.5% from its 52-week high of $212.75. Relative strength versus the S&P 500 is -42.3% over one year and -50.1% YTD, indicating persistent institutional selling.
- Earnings volatility and estimate risk: Quarterly EPS has swung from -$1.75 (Q3 2025) to -$0.06 (Q2 2026), and the Q1 2026 loss of -$0.76 missed the improving trajectory, showing launch-related spending can still surprise. With a forward EPS estimate of $10.69 against a -$0.03 TTM EPS, the consensus requires a dramatic profitability inflection that may be delayed.
INSM Technical Analysis
Beta
0.82
0.82x market volatility
Max Drawdown
-56.5%
Largest decline past year
52-Week Range
$90-$213
Price range past year
Annual Return
-38.8%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -21.9% | +2.1% |
| 3m | -13.0% | +3.1% |
| 6m | -35.0% | +14.6% |
| 1y | -38.8% | +16.0% |
| ytd | -43.2% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Quarterly Revenue
$425486000.0B
2026-06
Revenue YoY Growth
+296.1%
YoY Comparison
Gross Margin
84.2%
Latest Quarter
Free Cash Flow
$-837669000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
PE
-27.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Insmed's financial risk profile is dominated by its cash burn: TTM free cash flow is -$837.7M, with Q2 2026 R&D of $210.0M and SG&A of $247.5M against revenue of $425.5M. While the current ratio of 3.83 provides near-term liquidity, the company remains unprofitable with a net margin of -2.1% and operating margin of -1.94%, and debt-to-equity of 1.04 means interest expense of ~$20M per quarter is a fixed burden. The revenue base is also concentrated in Arikayce and the newly launched Brinsupri (brensocatib), so any launch misstep or reimbursement headwind would directly hit the top line and delay the path to profitability.
Market and competitive risks are amplified by the stock's extreme valuation: a forward P/E of 143.4x, P/S of 61.3x, and P/B of 50.3x leave no room for error, and any multiple compression could be severe given the 56.5% max drawdown already experienced. Beta of 0.817 suggests lower market correlation, but the stock has massively underperformed the S&P 500 (relative strength -42.3% over one year), indicating sector-specific and company-specific selling pressure. Recent news highlights competitive threats in PAH from LQDA's Yutrepia against Insmed's TPIP/Tyvaso franchise, and the high short ratio of 5.74 means negative catalysts could be amplified by short selling.
The worst-case scenario would combine a brensocatib launch that fails to meet aggressive revenue expectations, a delay or rejection of the Arikayce label expansion, and continued cash burn forcing a dilutive equity raise. In that scenario, the stock could retest its 52-week low of $90.39 — a decline of roughly 18.6% from the current $111.12 — and if the analyst low target of $169 is abandoned, a break below the 52-week low toward the $80s is possible, implying a 25-30% drawdown. Given the max drawdown of -56.5% from the 52-week high of $212.75, investors should be prepared for similar volatility if execution disappoints.
FAQ
The most severe risk is financial: TTM free cash flow is -$837.7M, with Q2 2026 R&D of $210.0M and SG&A of $247.5M, meaning the company remains unprofitable and dependent on external financing or a rapid revenue ramp. Second is valuation compression risk: at a forward P/E of 143.4x and P/S of 61.3x, any revenue miss or launch disappointment could trigger a sharp multiple reset, as already seen in the -56.5% max drawdown. Third is competitive risk: LQDA's Yutrepia is emerging as a threat in PAH, and brensocatib faces potential competition in bronchiectasis. Fourth is regulatory/company-specific risk: the Arikayce label expansion, though accepted with priority review, could still face delays or a complete response letter, removing a key near-term catalyst. Ranked by severity: cash burn, valuation, competition, regulatory.
The 12-month forecast has three scenarios: a bull case (25% probability) targeting $197-$243 if brensocatib launch exceeds expectations and Arikayce label expansion is approved, aligning with the analyst average target of $197.74 and high target of $243; a base case (50% probability) targeting $130-$170 if revenue grows but moderates, with the stock stabilizing above its 52-week low of $90.39; and a bear case (25% probability) targeting $90-$120 if the launch disappoints or regulatory delays occur, retesting the 52-week low. The base case is most likely, assuming no major safety or reimbursement setbacks and continued revenue growth toward $450-550M quarterly. The key assumption is that brensocatib adoption accelerates and free cash flow burn narrows, allowing the market to gain confidence in the path to profitability.
On current earnings, INSM is significantly overvalued: trailing P/E is -27.2x (negative earnings), forward P/E is 143.4x, P/S is 61.3x, and P/B is 50.3x. These multiples are extreme even for a high-growth biotech and imply the market expects revenue to scale dramatically toward the $6.37B consensus estimate. On a forward basis, if the company hits the $10.69 average EPS estimate, the stock would trade at roughly 10.4x forward earnings — but that estimate requires a massive profitability inflection from the current -$0.03 TTM EPS. Relative to its own history, the stock is down 37.3% YTD and 27.3% over one year, suggesting the market has already de-rated it significantly. The valuation is a bet on execution: fairly valued if the launch succeeds, overvalued if growth stalls.
INSM is a high-risk, high-reward speculative buy for investors who can tolerate volatility and a multi-year horizon. The stock trades at $111.12, down 37.3% YTD, with a forward P/E of 143.4x and negative TTM free cash flow of -$837.7M, so it is not cheap on current fundamentals. However, 23 analysts rate it a strong buy with an average target of $197.74 (78% upside), and Q2 2026 revenue grew 296% YoY to $425.5M with EPS improving to -$0.06. The biggest downside risk is a brensocatib launch disappointment or Arikayce regulatory delay, which could send the stock back toward its 52-week low of $90.39 (-18.6%). It is a good buy only for risk-tolerant investors who believe the revenue ramp will continue and who can hold through potential 30-50% drawdowns.
INSM is best suited for long-term investors with a 3-5 year horizon who can tolerate significant volatility. The stock has a beta of 0.817 (lower than the market) but a max drawdown of -56.5% and a 37.3% YTD decline, indicating high idiosyncratic risk. The company pays no dividend (payout ratio 0, yield 0) and is in a heavy investment phase with -$837.7M TTM free cash flow, so returns depend entirely on capital appreciation from the brensocatib/Arikayce franchise. Earnings visibility is low given quarterly EPS swings from -$1.75 to -$0.06, making short-term trading highly speculative. A minimum holding period of 3 years is suggested to allow the commercial launch to mature and the pipeline (TPIP, INS1148, INS1201) to produce data. Short-term traders should note the high short ratio of 5.74 and potential for sharp moves around earnings and FDA decisions.
